Use of antiviral therapy in patients with chronic hepatitis C

Natalia Dragomiretskaya 1 , Anna Izha 1 , Nikolay Kalinichenko 1 , Mirosława Szark-Eckardt 2 , Mariusz Klimczyk 2 , Mirosława Cieślicka 2 , Radosław Muszkieta 2 , Krzysztof Prusik 2 , Marek Napierała 2 , Hanna Żukowska 2 , and Walery Zukow 3
  • 1 Ukrainian scientific research institute of medical rehabilitation and curortology Ministry of Health Ukraine, Odessa, Ukraine
  • 2 Faculty of Physical Culture, Health and Tourism, Kazimierz Wielki University, Bydgoszcz, Poland
  • 3 Faculty of Physical Culture, Health and Tourism, Kazimierz Wielki University, ul. Ogińskiego 16, 85-092 Bydgoszcz, Poland


Introduction: The presence of background HCV infection cannot be overestimated in view of the prevalence of chronic hepatitis C and the risk of adverse outcomes of this disease. Purpose of this study was to evaluate the effectiveness of the combined use of antiviral therapy (Roferon + Vero-Ribavirin) and resort factors in patients with chronic hepatitis C in the phase of replication. Material and methods: We observed 48 patients with chronic hepatitis C; the minimum level of activity of the process defined the phase of replication. Markers of HCV infection were determined by enzyme linked immunosorbent assay (ELISA) (a-HCV and HCV-Ig M). HCV RNA was determined twice by the polymerase chain reaction (PCR). Genotyping of hepatitis C virus was performed. Biochemical blood analysis and the study of HCV infection markers were carried out four times. Results of therapy were assessed immediately after the end of the resort (spa) treatment, then at 3, 6 and 12 months after starting treatment. At 12 months after starting treatment, all the observed patients had persistent clinical and biochemical remission. Elimination of the virus from the blood was noted in 56% of the control group and 74% of patients in the study group. Conclusions: For patients with moderately active HCV, the replication phase was characterized by asthenic-vegetative syndrome (100% of patients) with severe depression (22.92%), pain (77.08%) and dyspeptic syndrome (33.33%), moderate hypertransferaseemia (100%), slightly pronounced cholestasis (33% of patients), and signs of mesenchymal- inflammatory response.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Kharchenko NV, Babak OJ. Gastroenterology. K. 2007; 720. [Harchenko N.V., Babak O.Ja., Gastroenterologіja.— K.: 2007. — 720 s.] In Russian

  • [2] Degtyareva II. Clinical gastroenterology. Medical Information Agency 2004; 616. [Degtjareva I.I. Klinicheskaja gastrojenterologija. – M.: Medicinskoe informacionnoe agentstvo, 2004. – 616 s.] In Russian

  • [3] Dragomiretskaya NV. Early resort rehabilitation and restorative treatment in gastroenterology: Monograph. ORIDU Nadu, Odesa, 2007; 176. [Dragomireckaja N.V. Rannja kurortna reabіlіtacіja ta vіdnovljuval‘ne lіkuvannja v gastroenterologії: Monografіja. — Odesa, ORІDU NADU, 2007. — 176 s.] In Russian

  • [4] Dragomiretskaya NV. The effectiveness of health. Resort rehabilitation of patients with chronic hepatitis C. Int J Immunoreab 2001; 3: 112. [Dragomireckaja N.V. Jeffektivnost‘ kurortnoj reabilitacii bol‘nyh hronicheskim gepatitom S. International journal on immunoreabilitation. May 2001. – Vol. 3, 2. – P . 112.] In Russian

  • [5] Dragomiretskaya NV, Malykhina TI. Izha AN. The use of low-mineralized mineral water and cytrarginine in complex treatment of patients with chronic hepatitis C. Rus J Gastroenterol Hepatol Coloproctol 2005; 1: 11. [Dragomireckaja N.V., Malyhina T.I., Izha A.N. Primenenie malomineralizovannoj mineral‘noj vody i citrarginina v kompleksnom lechenii bol‘nyh hronicheskim gepatitom S. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. – 2005. - # 1. – S. 11.] In Russian

  • [6] Nikitin IG. Treatment of chronic hepatitis C: yesterday, today and tomorrow. Russian Journal of Gastroenterology, Hepatology, Coloproctology. - 2002. - # 6. - S. 11-16. [Nikitin I.G. Lechenie hronicheskogo gepatita S: vchera, segodnja, zavtra. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. – 2002. - # 6. – S. 11-16.] In Russian

  • [7] Podymova SD. Liver disease: a guide. - 4th ed. Rev. and add. - Moscow: JSC „Publishing House“ Medicine“, 2005. - 768. [Podymova S.D. Bolezni pecheni: rukovodstvo. — 4-e izd., pererab. i dop. — M.: OAO «Izdatel‘stvo «Medicina», 2005. — 768 s.] In Russian

  • [8] Fedorchenko SV. Chronic HCV –infection. Monograph. - K.: TNI „Medicine“, 2010. - 272. [Fedorchenko S.V. Hronicheskaja HCV -infekcija: monografija. – K.: VSI «Medicina», 2010. – 272 s.] In Russian

  • [9] Kharchenko NV. Treatment of patients with chronic hepatitis C. Modern gastroenterology gepatology. -2000. - # 2. - S. 60-63. [Harchenko N.V. Lechenie bol‘nyh hronicheskim gepatitom S. Suchasna gastroenterologіja і gepatologіja. – 2000. - # 2. – S. 60-63.] In Russian

  • [10] Affonso de Araujo FS, Courtouke C, Barone AA. Hepatitis C: shorter and better? Brasil J Inf Dis 2007; 11: 118-124

  • [11] Andriulli A, Mangia A, Iacobellis A, et al. Meta-analisis: the out come of antiviral therapy in HCV genotype 2 and 3 pa¬tients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404

  • [12] Hadziyannis S, Cheinquer H, Morgan T, et al. Prospective evaluation of early virologic response associated with peginterferon alfa-2a (PEGASIS) plus ribavirin therapy from a phase III, randomized, double-blind study examinity the effect of treatment duration and ribavirin dose. American Association for the study of Liver disease, 52nd Annual Meeting, November 9-13th 2001, Dallas, USA

  • [13] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: an up date. Hepatology 2009; 49: 1336-1374

  • [14] Mangia A, Minerva N, Bacca D, et al. Individualized treat¬ment duration for hepatitis C genotype 1 patients: randomized controlled trial. Hepatology 2007; 47: 43-50

  • [15] Poynard T, Mc Hutchinson JG, Goodman Z, et al. Isan «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211-218

  • [16] Wong JB, Mc Quillan GM, Mc Hutchinson JG, et al. Esti¬mating future hepatitis C morbidity, mortality and cots in the United States. Am J Public Health 2000; 90: 1562-1569

  • [17] Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski K. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit 2010; 16(3):CR137-143

  • [18] Pawlowska M, Pilarczyk M, Halota W. Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16(12):CR616-621

  • [19] Dragomiretskaya N., Shevchenko N., Izha G., Zabolotnaya I., Kalinichenko N., & Zukow, W. Application of natural and physical factors is in treatment of patients with chronic viral hepatitis S - ground of the use. Journal of Health Sciences. 2013; 3(4): 153-163

  • [20] Dragomiretskaya N., Zabolotnaya I., Izha A., Shevchenko N., & Kalinichenko N. Results and prospects of further development of early rehabilitation and recovery treatment health patients with gastroenterological profile in Ukraine (native studies). 2012; 2(6): 42-54

  • [21] Dragomiretska N.V., Izha G.M., Zabolotna I.B., Kalinichenko M.V., Shevchenko N.O. Clinical experience of complex application of antiviral therapy, natural and preformed physical factors in patients with chronic hepatitis C. Gastroenterologia. 2013; 47(1):. 1:60-64. Actual problems of transport medicine. 2012; 4(30):117-123

  • [22] Dragomiretskaya N.V., Fedirko A.M. Irritable bowel syndrome: an opportunity for new approaches of treatment. Medical rehabilitation, curortology, physiotherapy. 2011; 1(65):31-35

  • [23] Dragomiretskaya N.V., Zabolotnaya I.B., Malykhina T.I., Izha A.N., Shevchenko N.A., Kalinichenko N.V. Viral hepatitis: standard therapy and usage of natural factors. Sovremennaya gastroenterologia. 2011; 6 (62):92-98


Journal + Issues